APO RESEARCH · REPORT
Anti-Venom
Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings.
Product & engineering
Understand the product.
Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings.
Selected research
Industry Growth & Trends
Global Anti-Venom Industry Growth and Trends Forecast to 2032
Market perspective
Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings.
CSL is the world leading manufacturer in global Anti-Venom market with the market share of 27%, in terms of revenue, followed by Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech and MicroPharm. These 11 companies accounted for 68% of the revenue market share in 2019. Asia-Pacific, Middle East and Africa are the largest consumption regions, occupied about 77% of market share, in terms of volume. The application of Anti-Venom in hospital and clinics take the main global shares. The polyvalent Anti-Venom takes more global revenue shares compared to the Monovalent Anti-Venom, which accounts for 67% in 2019.
Report Scope
Read the full market overview
This report provides a structured, data-driven view of the global Anti-Venom market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Anti-Venom market size, estimates, and forecasts are presented in terms of sales volume (K Vials) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Anti-Venom market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Anti-Venom.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading manufacturers in the global Anti-Venom market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Anti-Venom Market by Company
CSL
Merck
BTG
Pfizer
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech
MicroPharm
Anti-Venom Segment by Type
Polyvalent Anti-Venom
Monovalent Anti-Venom
Anti-Venom Segment by Application
Non-profit Institutions
Hospitals and Clinic
Anti-Venom Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Venom market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-Venom and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Venom.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-Venom manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Anti-Venom in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Polyvalent Anti-Venom
- Monovalent Anti-Venom
Applications
- Non-profit Institutions
- Hospitals and Clinic
Companies covered
- CSL
- Merck
- BTG
- Pfizer
- Haffkine Bio-Pharmaceutical
- Rare Disease Therapeutics
- Flynn Pharma
- Vins Bioproducts
- Bharat Serums and Vaccines
- Serum Biotech
- MicroPharm
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Anti-Venom Market Size Estimates and Forecasts (2021-2032)
- 1.2.2 Global Anti-Venom Sales Estimates and Forecasts (2021-2032)
- 1.3 Anti-Venom Market by Type
- 1.3.1 Polyvalent Anti-Venom
- 1.3.2 Monovalent Anti-Venom
- 1.4 Global Anti-Venom Market Size by Type
- 1.4.1 Global Anti-Venom Market Size Overview by Type (2021-2032)
- 1.4.2 Global Anti-Venom Historic Market Size Review by Type (2021-2026)
- 1.4.3 Global Anti-Venom Forecasted Market Size by Type (2027-2032)
- 1.5 Key Regions Market Size by Type
- 1.5.1 North America Anti-Venom Sales Breakdown by Type (2021-2026)
- 1.5.2 Europe Anti-Venom Sales Breakdown by Type (2021-2026)
- 1.5.3 Asia-Pacific Anti-Venom Sales Breakdown by Type (2021-2026)
- 1.5.4 South America Anti-Venom Sales Breakdown by Type (2021-2026)
- 1.5.5 Middle East and Africa Anti-Venom Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
- 2.1 Anti-Venom Industry Trends
- 2.2 Anti-Venom Industry Drivers
- 2.3 Anti-Venom Industry Opportunities and Challenges
- 2.4 Anti-Venom Industry Restraints
3 Market Competitive Landscape by Company
- 3.1 Global Top Players by Anti-Venom Revenue (2021-2026)
- 3.2 Global Top Players by Anti-Venom Sales (2021-2026)
- 3.3 Global Top Players by Anti-Venom Price (2021-2026)
- 3.4 Global Anti-Venom Industry Company Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Anti-Venom Major Company Production Sites & Headquarters
- 3.6 Global Anti-Venom Company, Product Type & Application
- 3.7 Global Anti-Venom Company Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Anti-Venom Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Anti-Venom Players Market Share by Revenue in 2025
- 3.8.3 2025 Anti-Venom Tier 1, Tier 2, and Tier 3
4 Anti-Venom Regional Status and Outlook
- 4.1 Global Anti-Venom Market Size and CAGR by Region: 2021 VS 2025 VS 2032
- 4.2 Global Anti-Venom Historic Market Size by Region
- 4.2.1 Global Anti-Venom Sales in Volume by Region (2021-2026)
- 4.2.2 Global Anti-Venom Sales in Value by Region (2021-2026)
- 4.2.3 Global Anti-Venom Sales (Volume & Value), Price and Gross Margin (2021-2026)
- 4.3 Global Anti-Venom Forecasted Market Size by Region
- 4.3.1 Global Anti-Venom Sales in Volume by Region (2027-2032)
- 4.3.2 Global Anti-Venom Sales in Value by Region (2027-2032)
- 4.3.3 Global Anti-Venom Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Anti-Venom by Application
- 5.1 Anti-Venom Market by Application
- 5.1.1 Non-profit Institutions
- 5.1.2 Hospitals and Clinic
- 5.2 Global Anti-Venom Market Size by Application
- 5.2.1 Global Anti-Venom Market Size Overview by Application (2021-2032)
- 5.2.2 Global Anti-Venom Historic Market Size Review by Application (2021-2026)
- 5.2.3 Global Anti-Venom Forecasted Market Size by Application (2027-2032)
- 5.3 Key Regions Market Size by Application
- 5.3.1 North America Anti-Venom Sales Breakdown by Application (2021-2026)
- 5.3.2 Europe Anti-Venom Sales Breakdown by Application (2021-2026)
- 5.3.3 Asia-Pacific Anti-Venom Sales Breakdown by Application (2021-2026)
- 5.3.4 South America Anti-Venom Sales Breakdown by Application (2021-2026)
- 5.3.5 Middle East and Africa Anti-Venom Sales Breakdown by Application (2021-2026)
6 Company Profiles
- 6.1 CSL
- 6.1.1 CSL Company Information
- 6.1.2 CSL Business Overview
- 6.1.3 CSL Anti-Venom Sales, Revenue and Gross Margin (2021-2026)
- 6.1.4 CSL Anti-Venom Product Portfolio
- 6.1.5 CSL Recent Developments
- 6.2 Merck
- 6.2.1 Merck Company Information
- 6.2.2 Merck Business Overview
- 6.2.3 Merck Anti-Venom Sales, Revenue and Gross Margin (2021-2026)
- 6.2.4 Merck Anti-Venom Product Portfolio
- 6.2.5 Merck Recent Developments
- 6.3 BTG
- 6.3.1 BTG Company Information
- 6.3.2 BTG Business Overview
- 6.3.3 BTG Anti-Venom Sales, Revenue and Gross Margin (2021-2026)
- 6.3.4 BTG Anti-Venom Product Portfolio
- 6.3.5 BTG Recent Developments
- 6.4 Pfizer
- 6.4.1 Pfizer Company Information
- 6.4.2 Pfizer Business Overview
- 6.4.3 Pfizer Anti-Venom Sales, Revenue and Gross Margin (2021-2026)
- 6.4.4 Pfizer Anti-Venom Product Portfolio
- 6.4.5 Pfizer Recent Developments
- 6.5 Haffkine Bio-Pharmaceutical
- 6.5.1 Haffkine Bio-Pharmaceutical Company Information
- 6.5.2 Haffkine Bio-Pharmaceutical Business Overview
- 6.5.3 Haffkine Bio-Pharmaceutical Anti-Venom Sales, Revenue and Gross Margin (2021-2026)
- 6.5.4 Haffkine Bio-Pharmaceutical Anti-Venom Product Portfolio
- 6.5.5 Haffkine Bio-Pharmaceutical Recent Developments
- 6.6 Rare Disease Therapeutics
- 6.6.1 Rare Disease Therapeutics Company Information
- 6.6.2 Rare Disease Therapeutics Business Overview
- 6.6.3 Rare Disease Therapeutics Anti-Venom Sales, Revenue and Gross Margin (2021-2026)
- 6.6.4 Rare Disease Therapeutics Anti-Venom Product Portfolio
- 6.6.5 Rare Disease Therapeutics Recent Developments
- 6.7 Flynn Pharma
- 6.7.1 Flynn Pharma Company Information
- 6.7.2 Flynn Pharma Business Overview
- 6.7.3 Flynn Pharma Anti-Venom Sales, Revenue and Gross Margin (2021-2026)
- 6.7.4 Flynn Pharma Anti-Venom Product Portfolio
- 6.7.5 Flynn Pharma Recent Developments
- 6.8 Vins Bioproducts
- 6.8.1 Vins Bioproducts Company Information
- 6.8.2 Vins Bioproducts Business Overview
- 6.8.3 Vins Bioproducts Anti-Venom Sales, Revenue and Gross Margin (2021-2026)
- 6.8.4 Vins Bioproducts Anti-Venom Product Portfolio
- 6.8.5 Vins Bioproducts Recent Developments
- 6.9 Bharat Serums and Vaccines
- 6.9.1 Bharat Serums and Vaccines Company Information
- 6.9.2 Bharat Serums and Vaccines Business Overview
- 6.9.3 Bharat Serums and Vaccines Anti-Venom Sales, Revenue and Gross Margin (2021-2026)
- 6.9.4 Bharat Serums and Vaccines Anti-Venom Product Portfolio
- 6.9.5 Bharat Serums and Vaccines Recent Developments
- 6.10 Serum Biotech
- 6.10.1 Serum Biotech Company Information
- 6.10.2 Serum Biotech Business Overview
- 6.10.3 Serum Biotech Anti-Venom Sales, Revenue and Gross Margin (2021-2026)
- 6.10.4 Serum Biotech Anti-Venom Product Portfolio
- 6.10.5 Serum Biotech Recent Developments
- 6.11 MicroPharm
- 6.11.1 MicroPharm Company Information
- 6.11.2 MicroPharm Business Overview
- 6.11.3 MicroPharm Anti-Venom Sales, Revenue and Gross Margin (2021-2026)
- 6.11.4 MicroPharm Anti-Venom Product Portfolio
- 6.11.5 MicroPharm Recent Developments
7 North America by Country
- 7.1 North America Anti-Venom Sales by Country
- 7.1.1 North America Anti-Venom Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.1.2 North America Anti-Venom Sales by Country (2021-2026)
- 7.1.3 North America Anti-Venom Sales Forecast by Country (2027-2032)
- 7.2 North America Anti-Venom Market Size by Country
- 7.2.1 North America Anti-Venom Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2.2 North America Anti-Venom Market Size by Country (2021-2026)
- 7.2.3 North America Anti-Venom Market Size Forecast by Country (2027-2032)
8 Europe by Country
- 8.1 Europe Anti-Venom Sales by Country
- 8.1.1 Europe Anti-Venom Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.1.2 Europe Anti-Venom Sales by Country (2021-2026)
- 8.1.3 Europe Anti-Venom Sales Forecast by Country (2027-2032)
- 8.2 Europe Anti-Venom Market Size by Country
- 8.2.1 Europe Anti-Venom Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2.2 Europe Anti-Venom Market Size by Country (2021-2026)
- 8.2.3 Europe Anti-Venom Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
- 9.1 Asia-Pacific Anti-Venom Sales by Country
- 9.1.1 Asia-Pacific Anti-Venom Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.1.2 Asia-Pacific Anti-Venom Sales by Country (2021-2026)
- 9.1.3 Asia-Pacific Anti-Venom Sales Forecast by Country (2027-2032)
- 9.2 Asia-Pacific Anti-Venom Market Size by Country
- 9.2.1 Asia-Pacific Anti-Venom Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2.2 Asia-Pacific Anti-Venom Market Size by Country (2021-2026)
- 9.2.3 Asia-Pacific Anti-Venom Market Size Forecast by Country (2027-2032)
10 South America by Country
- 10.1 South America Anti-Venom Sales by Country
- 10.1.1 South America Anti-Venom Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.1.2 South America Anti-Venom Sales by Country (2021-2026)
- 10.1.3 South America Anti-Venom Sales Forecast by Country (2027-2032)
- 10.2 South America Anti-Venom Market Size by Country
- 10.2.1 South America Anti-Venom Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2.2 South America Anti-Venom Market Size by Country (2021-2026)
- 10.2.3 South America Anti-Venom Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
- 11.1 Middle East and Africa Anti-Venom Sales by Country
- 11.1.1 Middle East and Africa Anti-Venom Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.1.2 Middle East and Africa Anti-Venom Sales by Country (2021-2026)
- 11.1.3 Middle East and Africa Anti-Venom Sales Forecast by Country (2027-2032)
- 11.2 Middle East and Africa Anti-Venom Market Size by Country
- 11.2.1 Middle East and Africa Anti-Venom Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2.2 Middle East and Africa Anti-Venom Market Size by Country (2021-2026)
- 11.2.3 Middle East and Africa Anti-Venom Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
- 12.1 Anti-Venom Value Chain Analysis
- 12.1.1 Anti-Venom Key Raw Materials
- 12.1.2 Key Raw Materials Price
- 12.1.3 Raw Materials Key Suppliers
- 12.1.4 Manufacturing Cost Structure
- 12.1.5 Anti-Venom Production Mode & Process
- 12.2 Anti-Venom Sales Channels Analysis
- 12.2.1 Direct Comparison with Distribution Share
- 12.2.2 Anti-Venom Distributors
- 12.2.3 Anti-Venom Customers
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst